Dallas-Fort Worth, TX, April 19, 2016 – Texas Center for Proton Therapy and IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions for the treatment of cancer, announce the first patient treated in North America with the center’s high-precision tandem of iscocentric Cone Beam CT (CBCT) guidance and pencil beam scanning in a 360° Proteus®PLUS gantry.
Pencil beam scanning radiates tumors with an ultra-fine proton beam that requires precise positioning of the patient to ensure treatment accuracy. IBA’s ProteusPLUS 360º gantry allows the acquisition of CBCT volumetric imaging at isocenter to assure precise patient positioning that effectively leverages the power of pencil beam scanning to provide the most accurate proton therapy treatment available. This unique combination of technologies allows Texas Center for Proton Therapy to provide treatment for indications demanding the utmost precision, while leading the way to adaptive proton therapy and improved patient outcomes.
The multi-room ProteusPLUS installation at the Texas Center for Proton Therapy has been in clinical operation since November 2015 and represents the fastest ramp-up from ground-breaking to robust patient treatment volumes. The skilled center staff, combining more than 75 years of cumulative proton experience, has created a workflow that optimizes efficiency and patient comfort, while delivering outstanding clinical care with the most reliable equipment on the market.
Dr. Andrew K. Lee, M.D., M.P.H., Medical Director at Texas Center for Proton Therapy, commented:
“The combination of volumetric CBCT image guidance and pencil beam scanning begins a new era in proton therapy. This will allow proton therapy to help a wider range of cancer patients while improving the treatment for currently treated indications. This vital technology will help fulfill our joint mission to protect, enhance, and save lives.”
Beth Klein, President of IBA Proton Therapy North America, added:
“The Texas Center for Proton Therapy has implemented a powerful clinical tool in the fight against cancer and IBA is a proud partner in their effort to deliver advanced Proton Therapy treatment and improve the quality of life for cancer patients and their families in the Dallas-Fort Worth area.”
Read more news about IBA and proton therapy here.
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1,200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com.